# US 2018/0021344 A1 · Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021344 A1
- Document ID: US20180021344A1
- Status: Published application
- Kind: A1
- Application number: 15/671,792
- Filed: 2017-08-08
- Published: 2018-01-25
- Earliest claimed: 2014-11-14
- Assignees: Essentialis, Inc.
- Applicants: Essentialis, Inc.
- Inventors: Neil M. COWEN
- Web page: https://patentgrep.com/patent/US20180021344A1

## CPC

- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 285/18: 1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D 285/22: condensed with one six-membered ring
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of increasing by at least 2% the lean body mass or the lean body mass/fat mass ratio in a subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS), comprising administering to the subject for at least 10 weeks a pharmaceutical formulation comprising an effective amount of a KATP channel opener or a pharmaceutically acceptable salt thereof, wherein said lean body mass or lean body mass/fat ratio in the subject is increased by at least 2% after 10 weeks of administration compared to lean body mass or lean body mass/fat ratio prior to the start of the administration.

### Claim 30 (depends on 29)

The method of claim 29, wherein the lean body mass or the lean body mass/fat mass ratio of the subject is increased by at least 3% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 31 (depends on 29)

The method of claim 29, wherein the lean body mass or the lean body mass/fat mass ratio of said subject is increased by at least 4% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 32 (depends on 29)

The method of claim 29, wherein the lean body mass or the lean body mass/fat mass ratio of said subject is increased by at least 5% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 33 (depends on 29)

The method of claim 29, wherein the pharmaceutical formulation further comprises at least one other active ingredient.

### Claim 34 (depends on 29)

The method of claim 29, wherein the pharmaceutical formulation comprises at least one excipient that affects the rate of release of the KATP channel opener or the pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 29)

The method of claim 29, wherein the pharmaceutical formulation comprises at least one excipient that delays release of the KATP channel opener or the pharmaeeutieaily acceptable salt thereof.

### Claim 36 (depends on 29)

The method of claim 29, further comprising administering human growth hormone to the subject.

### Claim 37 (depends on 36)

The method of claim 36, wherein the human growth hormone is co-administered.

### Claim 38 (depends on 36)

The method of claim 36, wherein the human growth hormone is administered by injection.

### Claim 39 (depends on 29)

The method of claim 29, wherein hyperphagia of the subject is reduced by at least 10% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 40 (depends on 39)

The method of claim 39, wherein hyperphagia of the subject is reduced by at least 20% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 41 (depends on 40)

The method of claim 40, wherein hyperphagia of the subject is reduced by at least 30% after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 42 (depends on 29)

The method of claim 29, wherein the subject's circulating concentration of IGF-1 is not increased after at least 10 weeks of administering the pharmaceutical formulation.

### Claim 43 (depends on 29)

The method of claim 29, wherein the pharmaceutical formulation is administered twice per day.

### Claim 44 (depends on 29)

The method of claim 29, wherein the pharmaceutical formulation is administered once per day.

### Claim 45 (depends on 29)

The method of claim 29, wherein the pharmaceutical compositions is administered for 1 or more years.

### Claim 46 (depends on 29)

The method of claim 29, wherein the KATP channel opener is diazoxide, or the pharmaceutical composition comprises a pharmaeeutieaily acceptable salt of diazoxide.

### Claim 47 (depends on 46)

The method of claim 46, wherein the pharmaceutically acceptable salt is diazoxide choline.

### Claim 48 (depends on 46)

The method of claim 46, wherein the diazoxide or a pharmaceutically acceptable salt thereof is administered orally.
